Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Fax: 781 275 7562

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

BigErvy Feb. 3 at 9:04 PM

$OCUL data may be released same time as earnings. Potential reward looking good for the risk at these prices.

0 · Reply

KimboIce Feb. 3 at 9:03 PM

$OCUL regardless of price drop , the MC is still $1.8 billion . Everyone has a grand conspiracy of recent SP drop. It could be as simple as the market is re-calibrating the value based on a small p.1 N prior to SOL-1 readout . Outside of DR funding , nothing has really changed data wise . I think previous high MC was due to more management huff and puff about how excellent things are going . Markets simply sniffed out the bullshit and waiting for hard data to justify high MC IMO.

0 · Reply

ChartSherpa Feb. 3 at 8:49 PM

$OCUL just want to point out that when $SNY acquired $PRVB in 2023, they also drove the price down by nearly 50% just before the announcement. Selling puts here

2 · Reply

nicky7 Feb. 3 at 8:36 PM

$OCUL let’s gooooooooo

0 · Reply

ShortSuckieTuckie Feb. 3 at 8:12 PM

$OCUL I couldn't resist.... another 1,000 shares at $8.37

2 · Reply

BJM111 Feb. 3 at 8:11 PM

I bought more $OCUL shares today. Unbelievable bargain down nearly 50 percent from recent high with no news and no change in thesis. I expect positive SOL1 results in the next few weeks.

0 · Reply

lilcapman Feb. 3 at 8:03 PM

$OCUL https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/

0 · Reply

greensmell Feb. 3 at 8:02 PM

$OCUL Entered a quite period in December for a Q1 readout while $GOSS CEO is out chilling at PVR (Jan 28-Feb 1) with data due in few weeks.😂 (from X @avidresearch)

0 · Reply

guidoriz Feb. 3 at 7:56 PM

$OCUL for sure will be happy who spent 400 million

0 · Reply

JFais Feb. 3 at 7:49 PM

$OCUL $MLTX The buyout rumor to provide exit liquidity is definitely a thing (& so illegal)

1 · Reply

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2025, 12:59 PM EST - 2 months ago

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Nov 4, 2025, 3:16 PM EST - 3 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:05 AM EST - 3 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 3 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 1, 2025, 4:22 AM EDT - 4 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Sep 30, 2025, 7:08 AM EDT - 4 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 4 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 8, 2025, 5:05 PM EDT - 5 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 1:52 AM EDT - 5 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Aug 5, 2025, 1:33 PM EDT - 6 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Jun 26, 2025, 1:54 PM EDT - 7 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 8 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 14, 2025, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 11, 2025, 2:49 PM EDT - 11 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 6, 2025, 11:15 AM EST - 11 months ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 3, 2025, 10:16 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 2:01 PM EDT - 1 year ago

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Jun 1, 2024, 5:30 AM EDT - 1 year ago

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 6, 2024, 8:16 PM EDT - 1 year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

BigErvy Feb. 3 at 9:04 PM

$OCUL data may be released same time as earnings. Potential reward looking good for the risk at these prices.

0 · Reply

KimboIce Feb. 3 at 9:03 PM

0 · Reply

ChartSherpa Feb. 3 at 8:49 PM

$OCUL just want to point out that when $SNY acquired $PRVB in 2023, they also drove the price down by nearly 50% just before the announcement. Selling puts here

2 · Reply

nicky7 Feb. 3 at 8:36 PM

$OCUL let’s gooooooooo

0 · Reply

ShortSuckieTuckie Feb. 3 at 8:12 PM

$OCUL I couldn't resist.... another 1,000 shares at $8.37

2 · Reply

BJM111 Feb. 3 at 8:11 PM

I bought more $OCUL shares today. Unbelievable bargain down nearly 50 percent from recent high with no news and no change in thesis. I expect positive SOL1 results in the next few weeks.

0 · Reply

lilcapman Feb. 3 at 8:03 PM

$OCUL https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/

0 · Reply

greensmell Feb. 3 at 8:02 PM

$OCUL Entered a quite period in December for a Q1 readout while $GOSS CEO is out chilling at PVR (Jan 28-Feb 1) with data due in few weeks.😂 (from X @avidresearch)

0 · Reply

guidoriz Feb. 3 at 7:56 PM

$OCUL for sure will be happy who spent 400 million

0 · Reply

JFais Feb. 3 at 7:49 PM

$OCUL $MLTX The buyout rumor to provide exit liquidity is definitely a thing (& so illegal)

1 · Reply

xMonti Feb. 3 at 7:28 PM

$OCUL potential target for buyout in 2026

1 · Reply

ReturnOfEsquire Feb. 3 at 7:27 PM

$OCUL Does anyone have a reasonably reliable data date? I might enter for a swing gamble.

1 · Reply

jac05010 Feb. 3 at 7:19 PM

$OCUL I AM going to sell. Cutting my losses- you know why? This management gave big money the opportunity to get out on two unconfirmed and likely false buyout rumors. Look at the shares offloaded in the 16's and the 12-13 range, plus the volume. There's approximately 14 million shares outstanding that are not owned by tutes. I ask you this seriously- Who is responsible for all this volume? It ain't retail. Think about it, buddy.

1 · Reply

moneybagged Feb. 3 at 7:14 PM

$OCUL Added another 10,000 shares😎$25

0 · Reply

The_Fudge_ster Feb. 3 at 7:12 PM

$OCUL yikes. Ugly.

1 · Reply

YosemiteSam83 Feb. 3 at 7:09 PM

$OCUL With every option transaction requiring both a buyer and seller, what's a rational translation for the Feb20$15 out-of-the-money Call volumes?

1 · Reply

KYLE0829 Feb. 3 at 6:57 PM

$OCUL @jac05010 shut the computer down for the day. You are panicking. It is not normal to comment on everyones post some negative bs. If it’s soooo terrible, sell. Otherwise grit your teeth and hold for a little while to see how it plays out.

1 · Reply

I_am_Sparta Feb. 3 at 6:52 PM

$OCUL

0 · Reply

Dukpoo Feb. 3 at 6:46 PM

$OCUL looks like this whole data thing aint gonna work out, everyone just dumping

0 · Reply

moneybagged Feb. 3 at 6:24 PM

$OCUL way oversold!!! what a gift!!!!

0 · Reply

esu89 Feb. 3 at 6:23 PM

$OCUL

1 · Reply

LinSmi Feb. 3 at 6:22 PM

$OCUL BUYERS IN CONTROL 🧲 – No sign of weakness as we approach 1.00. The next move? 1.10 and 1.20. 1.00 break = FOMO-powered explosion 🚀💥

0 · Reply

Market Cap	1.95B
Revenue (ttm)	63.72M
Net Income (ttm)	-193.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-303.69%
Debt to Equity Ratio	0.27

Volume	6,858,657
Avg Vol	4,219,714
Day's Range	N/A - N/A
Shares Out	213.05M
Stochastic %K	5%
Beta	0.93
Analysts	Strong Sell
Price Target	$23.38